Critical limb Ischemia Pipeline Review 2021

Critical limb Ischemia- Pipeline Review

Critical Limb Ischemia (CLI) is a chronic condition with most serious type of peripheral arterial disease (PAD). It’s a major obstruction in the arteries that extremely reduces blood flow to the extremities causing severe recurrent pain, and non-healing ulcers affecting millions of patients in U.S. and Europe. Symptoms of CLI includes severe burning pain in the feet or toes even at rest. It has limited treatment options and has a severe impact on the patient’s quality of life.

In the United States and Europe, Critical Limb Ischemia is a common condition affecting around 1-1.5% of the population over 40 years of age. Patients suffering from diabetes over 50 years of age has a prevalence of CLI of 5.8%. Growing ageing population and incidence of diabetes significantly increases the risk of both PAD and CLI

Rexgenero is a leading developer of advanced cell-based therapeutics and regenerative medicine company for the treatment of serious diseases that are weekly treated with current therapies. The company’s lead product REX-001 is a novel autologous cell therapy developed for the treatment of critical limb ischemia (CLI), succeeding highly encouraging results from three phase II studies which completed in 2016. Rexgenero is leading two pivotal, placebo-controlled, double-blind, adaptive Phase III trials in patients with CLI and Diabetes Mellitus (DM). The protocol of both trials, including the patient population and primary endpoints, has been fully certified by the European Medicines Agency (EMA).

Approximately 60% of pipeline drugs for Critical limb Ischemia are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Critical limb Ischemia.

Report Description

The report on Critical limb Ischemia- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Critical limb Ischemia. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Critical limb Ischemia (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

1. Introduction

• Objectives of the Study
• Definition
• Report Overview
• Critical limb Ischemia Overview

2. Executive Summary
3. Critical limb Ischemia: Pipeline Assessment

• Company Overview
• Product Description
• Status
• Phase
• Study Design
• Route of Administration
• Indication       
• Condition        
• NCT Number              
• Sponsor          
• Collaborator   
• Brief Title         
• Study Start Date         
• Study completion (Estimated/Actual)
• Study Completion Date
• Enrollment     
• Research Location (Listed Location Countries)

4. Critical limb Ischemia: Analysis on Dormant & Discontinued Pipeline Candidates

• Overview
• Product Description
• Reason for Discontinuation

5. Critical limb Ischemia: Additional Key Insights

• Epidemiology Overview: Critical limb Ischemia

6. Critical limb Ischemia: Press Releases, Latest News and Conference Details

Note:

• Table of Content is tentative and subject to change as the research progresses
• The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.